share_log

Guggenheim Initiates Coverage On Cidara Therapeutics With Buy Rating, Announces Price Target of $33

Benzinga ·  Nov 8, 2024 06:31  · Ratings

Guggenheim analyst Seamus Fernandez initiates coverage on Cidara Therapeutics (NASDAQ:CDTX) with a Buy rating and announces Price Target of $33.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment